The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.

Bundgaard, Henning; Axelsson, Anna; Hartvig Thomsen, Jakob; Sørgaard, Mathias; Kofoed, Klaus F; Hasselbalch, Rasmus B.; Fry, Natasha A S; Valeur, Nana; Boesgaard, Søren; Gustafsson, Finn; Køber, Lars; Iversen, Kasper; Rasmussen, Helge H

doi:10.1002/ejhf.714

Record: found
Abstract: found
Article: not found

The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial.

Author(s): Henning Bundgaard, Anna Axelsson, Jakob Hartvig Thomsen, Mathias Sørgaard, Klaus Kofoed, Rasmus B. Hasselbalch, Natasha A S Fry, Nana Valeur, Søren Boesgaard, Finn Gustafsson, Lars Køber, Kasper Iversen, Helge H Rasmussen

Publication date: 2017-04-01

Journal: European Journal of Heart Failure

Publisher: Wiley

Keywords: Membrane sodium-potassium pump, Heart failure, Neurohormonal activation, Adrenergic receptors, Cardiac contractility, Oxidant stress

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The third isotype of beta adrenergic receptors (β3 ARs) has distinctly different effects on cardiomyocytes compared with β1 and β2 ARs. Stimulation of β3 ARs may reduce cardiomyocyte Na+ overload and reduce oxidative stress in heart failure (HF). We examined if treatment with the β3 AR agonist mirabegron increases LVEF in patients with HF.